Two Trial Wins Cement Valneva’s Lead In Chikungunya

 
• By Kevin Grogan

As rival Bavarian Nordic closes in on US approval for its chikungunya vaccine for people aged 12 and older, the French biotech has presented positive data for its already-approved jab Ixchiq in adolescents and children.

Valneva Vienna
• Source: Valneva

More from Strategy

More from Therapy Areas